Atorlip 5: Expert Cholesterol Management with Atorvastatin
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.72 | $43.11 (0%) | 🛒 Add to cart |
| 90 | $0.60 | $64.67 $54.14 (16%) | 🛒 Add to cart |
| 120 | $0.55 | $86.23 $66.17 (23%) | 🛒 Add to cart |
| 180 | $0.49 | $129.34 $88.23 (32%) | 🛒 Add to cart |
| 270 | $0.46 | $194.01 $123.32 (36%) | 🛒 Add to cart |
| 360 | $0.44
Best per pill | $258.68 $157.41 (39%) | 🛒 Add to cart |
Similar products
Atorlip 5 is a prescription medication containing atorvastatin calcium, specifically formulated to address elevated cholesterol levels and support cardiovascular health. As a member of the statin class, it works by inhibiting HMG-CoA reductase, a key enzyme in the liver responsible for cholesterol production. This medication is indicated for patients requiring pharmacological intervention to lower LDL cholesterol, reduce triglycerides, and increase HDL cholesterol, thereby decreasing the risk of atherosclerotic cardiovascular disease. Under professional supervision, Atorlip 5 offers a targeted approach to lipid management, aligning with current clinical guidelines for dyslipidemia treatment.
Features
- Active ingredient: Atorvastatin calcium 5 mg per tablet
- Pharmaceutical form: Film-coated tablets
- Mechanism: Selective, competitive inhibitor of HMG-CoA reductase
- Bioavailability: Approximately 12%
- Half-life: 14 hours; active metabolites contribute to prolonged effect
- Excretion: Primarily via hepatic metabolism and biliary excretion
- Pack sizes: Available in blisters of 10, 28, or 30 tablets
Benefits
- Significantly reduces low-density lipoprotein (LDL) cholesterol levels by up to 39% at the 5 mg dose
- Lowers triglyceride concentrations and modestly raises high-density lipoprotein (HDL) cholesterol
- Decreases the risk of myocardial infarction, stroke, and revascularization procedures in high-risk patients
- Provides 24-hour lipid-lowering efficacy with once-daily dosing
- Offers a well-tolerated option for long-term cholesterol management
- Supported by extensive clinical trial data demonstrating cardiovascular risk reduction
Common use
Atorlip 5 is primarily prescribed for the treatment of hypercholesterolemia, including heterozygous familial and non-familial forms, as well as mixed dyslipidemia. It is indicated as an adjunct to diet when dietary and other non-pharmacological measures alone are insufficient. In clinical practice, it is also used for primary prevention of cardiovascular events in patients with multiple risk factors, and for secondary prevention in those with established coronary heart disease. The 5 mg strength is often initiated in patients requiring moderate LDL reduction or those with increased susceptibility to side effects.
Dosage and direction
The recommended starting dose is Atorlip 5 (5 mg) once daily, which may be adjusted based on lipid response and tolerability after 2-4 weeks. Dosage can be titrated up to a maximum of 80 mg daily if necessary. Administration is oral, with or without food, preferably at the same time each day. Tablets should be swallowed whole with water and not crushed or chewed. Dose adjustments are required in patients with renal impairment or those taking certain concomitant medications. Liver function tests should be performed before initiation and periodically during treatment.
Precautions
Liver function monitoring is essential before starting treatment and periodically thereafter. Patients should report any unexplained muscle pain, tenderness, or weakness immediately. Blood glucose levels should be monitored, as statins may increase HbA1c and fasting serum glucose levels. Use with caution in patients with a history of liver disease, excessive alcohol consumption, or those undergoing major surgery. Ophthalmological examination is recommended if visual disturbances occur. Not recommended during pregnancy or in women of childbearing potential not using contraception.
Contraindications
Atorlip 5 is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases. It must not be used during pregnancy, lactation, or in women of childbearing age not using effective contraception. Hypersensitivity to atorvastatin or any excipients in the formulation prohibits use. Concomitant administration with strong CYP3A4 inhibitors such as itraconazole, ketoconazole, or certain HIV protease inhibitors is contraindicated. Patients with acute porphyria should avoid this medication.
Possible side effect
Common adverse reactions (≥1/100 to <1/10) include headache, insomnia, nausea, diarrhea, dyspepsia, myalgia, and arthralgia. Uncommon effects (≥1/1,000 to <1/100) may consist of constipation, flatulence, dizziness, rash, pruritus, and asthenia. Rare but serious side effects include rhabdomyolysis with renal dysfunction, hepatitis, pancreatitis, and peripheral neuropathy. Increased liver enzymes occur in approximately 0.7% of patients. Hypersensitivity reactions including angioedema and anaphylaxis have been reported rarely.
Drug interaction
Atorvastatin is metabolized primarily by CYP3A4, resulting in significant interactions with inhibitors and inducers of this enzyme system. Concomitant use with cyclosporine, gemfibrozil, or niacin increases the risk of myopathy. Antacids containing magnesium and aluminum hydroxide decrease atorvastatin absorption. Warfarin coadministration may potentiate anticoagulant effect requiring INR monitoring. Digoxin levels may increase slightly with concurrent administration. Oral contraceptives containing ethinyl estradiol and norgestrel show increased AUC when coadministered with atorvastatin.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is nearly time for the next scheduled dose, the missed dose should be skipped entirely. Patients should not take a double dose to make up for a missed one. Consistent daily administration is important for maintaining stable lipid-lowering effects. If multiple doses are missed, consultation with a healthcare provider is recommended before resuming therapy.
Overdose
There is no specific antidote for atorvastatin overdose. Symptomatic and supportive measures should be instituted as required. In case of recent ingestion, gastric lavage may be considered along with activated charcoal to reduce absorption. Liver function and CPK levels should be monitored closely. Hemodialysis is not expected to significantly enhance elimination since atorvastatin is extensively protein bound. Cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with massive overdose.
Storage
Store at room temperature (15-30°C) in the original packaging to protect from light and moisture. Keep the container tightly closed and out of reach of children. Do not use after the expiration date printed on the packaging. Tablets should not be removed from blister strips until immediately before administration. Avoid storage in bathrooms or other areas with high humidity or temperature fluctuations.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Atorlip 5 is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to therapy may vary, and proper medical supervision is essential throughout treatment. Patients should not initiate, adjust, or discontinue medication without consulting their physician. The complete prescribing information should be consulted before administration.
Reviews
Clinical studies demonstrate that atorvastatin 5 mg effectively reduces LDL cholesterol by approximately 30-39% in most patients, with good overall tolerability. In the ASCOT-LLA trial, atorvastatin 10 mg (the closest studied dose) reduced coronary events by 36% in hypertensive patients with additional risk factors. Real-world evidence supports the efficacy and safety profile observed in clinical trials, with particular appreciation for the flexibility in dosing titration. Some patients report gastrointestinal discomfort during the initial treatment period, which typically resolves with continued use. The balance between efficacy and side effect profile makes Atorlip 5 a valuable option in the statin arsenal.